Dermira (NASDAQ:DERM) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 7th. Analysts expect Dermira to post earnings of ($1.98) per share for the quarter.
Dermira (NASDAQ:DERM) last announced its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.57) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.57). The business had revenue of $39.08 million during the quarter, compared to the consensus estimate of $39.00 million. Dermira had a negative net margin of 761.87% and a negative return on equity of 128.21%. On average, analysts expect Dermira to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Shares of Dermira stock opened at $11.88 on Tuesday. The stock has a market capitalization of $536.26 million, a price-to-earnings ratio of -2.71 and a beta of 0.96. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 2.49. Dermira has a one year low of $6.98 and a one year high of $31.42.
A number of equities analysts have commented on DERM shares. BidaskClub downgraded shares of Dermira from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 19th. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a report on Tuesday, July 31st. Cantor Fitzgerald set a $20.00 target price on shares of Dermira and gave the stock a “buy” rating in a report on Monday, August 6th. ValuEngine upgraded shares of Dermira from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 2nd. Finally, Mizuho reiterated a “hold” rating and issued a $10.00 target price on shares of Dermira in a report on Tuesday, October 2nd. Four research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $22.86.
In related news, Director Matthew K. Fust sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, October 19th. The stock was sold at an average price of $13.75, for a total value of $55,000.00. Following the sale, the director now owns 14,051 shares in the company, valued at $193,201.25. The sale was disclosed in a legal filing with the SEC, which is available through this link. 14.80% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/11/06/dermira-derm-to-release-earnings-on-wednesday.html.
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
See Also: Do Tariffs Work?
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.